Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues
Reexamination Certificate
2011-07-05
2011-07-05
Reddig, Peter J (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
C530S324000, C514S001100, C514S019200, C514S019300, C514S019400, C536S023100, C536S023400, C435S320100, C435S325000, C435S355000
Reexamination Certificate
active
07973128
ABSTRACT:
The present invention pertains to the field of anti-cancer vaccines. More particularly, the invention concerns an optimized polypeptide, which comprises three cryptic tumor peptides with enhanced immunogenicity and comprises the amino acids sequence YLQVNSLQTVYLEYRQVPVYLEEITGYL (SEQ ID NO. 2), for use in an anti-cancer vaccine. Nucleic acids encoding such a polypeptide, as well as complexes and dendritic cells engineered with this polypeptide or a nucleic acid encoding it, are also part of the invention.
REFERENCES:
patent: 2004/0072240 (2004-04-01), Kosmatopoulos et al.
patent: 1 568 373 (2005-08-01), None
patent: WO 01/85932 (2001-11-01), None
Suhrbier A. (Expert Rev. Vaccines 2002 1:207-213).
Velders et al. (J. Immunol. 2001 166:5366-5373).
Thomson et al. (J. Virol. 1998 72:2246-2252).
Wang et al. (J. Immunol. 1998 161-5516-5524).
Search Report and Written Opinion for International Application No. PCT/EP2005/014212, filed Dec. 23, 2005.
Mateo L et al: “An HLA-A2 polyepitope vaccine for melanoma immunotherapy”; Journal of Immunology, The Williams and Wilkins Co. Baltimore, US; vol. 163, No. 7; Oct. 1, 1999; pp. 4058-4063; XP002244411.
Scardino A et al: “Her-2/Neu and HTERT Cryptic Epitopes as Novel Targets for Broad Spectrum Tumor Immunotherapy”; Journal of Immunology, The Williams and Wilkins Co. Baltimore, US; vol. 168, No. 11; Jun. 1, 2000; pp. 5900-5906; XP001126974.
Graff-Dubois S et al: “Generation of CTL Recognizing an HLA-A 0201 Restricted Epitope Shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 Tumor Antigens: Implication in a Broad-Spectrum Tumor Immunotherapy”; Journal of Immunology, The Williams and Wilkins Co. Baltimore, US; vol. 169, No. 1, 2002; pp. 575-580; XP001109368.
Alexander Jeff et al: “A decaepitope polypeptide primes for multiple CD8+ IFN-gamma and Th lymphocyte responses: Evaluation of multiepitope polypeptides as a mode for vaccine delivery”; Journal of Immunology; vol. 168, No. 12; Jun. 15, 2002; pp. 6189-6198; XP002372921.
Cornet Sebastien et al: “Optimal organization of a polypeptide-based candidate cancer vaccine composed of cryptic tumor peptides with enhanced immunogenicity”; Vaccine; Mar. 15, 2006; vol. 24, No. 12; pp. 2102-2109; XP002372922.
Cornet Sébastien
Kosmatopoulos Kostantinos
Alston & Bird LLP
Reddig Peter J
Vaxon Biotech
LandOfFree
Immunogenic polypeptide composed of tumor antigen-derived... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunogenic polypeptide composed of tumor antigen-derived..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunogenic polypeptide composed of tumor antigen-derived... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2653945